Benefits of high-dose, high-frequency interferon beta-1a in relapsing-remitting multiple sclerosis are sustained to 16 months: Final comparative results of the EVIDENCE trial

被引：72

作者：

Panitch, H

Goodin, D

Francis, G

Chang, P

Coyle, P

O'Connor, P

Li, D

Weinshenker, B

机构：

[1] Univ Vermont, Coll Med, Neurol Hlth Care Serv, Burlington, VT 05401 USA

[2] Univ Calif San Francisco, San Francisco, CA 94143 USA

[3] Serono Inc, Rockland, MA USA

[4] SUNY Stony Brook, Univ Hosp, Med Ctr, Stony Brook, NY USA

[5] Univ Toronto, St Michaels Hosp, Toronto, ON, Canada

[6] Univ British Columbia, Vancouver, BC V5Z 1M9, Canada

[7] Mayo Clin, Rochester, MN USA

来源：

JOURNAL OF THE NEUROLOGICAL SCIENCES | 2005年 / 239卷 / 01期

关键词：

comparative study; interferon beta; magnetic resonance imaging (MRI); multiple sclerosis (MS); neutralizing antibodies;

D O I：

10.1016/j.jns.2005.08.003

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

The EVIDENCE trial demonstrated that interferon (IFN) beta-la, 44 mcg subcutaneously (sc) three times weekly (tiw) (Rebif (R)), was significantly more effective than IFN beta-1a, 30 mcg intramuscularly (im) once weekly (qw) (Avonex (R)), in reducing relapses and magnetic resonance imaging (MRI) activity in patients with relapsing-remitting multiple sclerosis at both 24 and 48 weeks of therapy. We now present final comparative data on these patients, showing that the superior efficacy of IFN beta-1a, 44mcg sc tiw, for relapse measures and MRI activity. compared with IFN beta-la, 30mcg im qw, was sustained for at least 16 months. The development of antibodies to IFN was associated with reduced efficacy on MRI measures and fewer IFN-related adverse events, but did not have an impact on relapse outcomes. (c) 2005 Elsevier B.V. All rights reserved.

引用

页码：67 / 74

页数：8

共 18 条

[1] A comparison of the biologic activity of two recombinant IFN-β preparations used in the treatment of relapsing-remitting multiple sclerosis [J].

Antonetti, F ;

Finocchiaro, O ;

Mascia, M ;

Terlizzese, MG ;

Jaber, A .

JOURNAL OF INTERFERON AND CYTOKINE RESEARCH, 2002, 22 (12) :1181-1184

[2] INTERFERON BETA-1B IS EFFECTIVE IN RELAPSING-REMITTING MULTIPLE-SCLEROSIS - CLINICAL-RESULTS OF A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL [J].

DUQUETTE, P ;

GIRARD, M ;

DESPAULT, L ;

DUBOIS, R ;

KNOBLER, RL ;

LUBLIN, FD ;

KELLEY, L ;

FRANCIS, GS ;

LAPIERRE, Y ;

ANTEL, J ;

FREEDMAN, M ;

HUM, S ;

GREENSTEIN, JI ;

MISHRA, B ;

MULDOON, J ;

WHITAKER, JN ;

EVANS, BK ;

LAYTON, B ;

SIBLEY, WA ;

LAGUNA, J ;

KRIKAWA, J ;

PATY, DW ;

OGER, JJ ;

KASTRUKOFF, LF ;

MOORE, GRW ;

HASHIMOTO, SA ;

MORRISON, W ;

NELSON, J ;

GOODIN, DS ;

MASSA, SM ;

GUTTERIDGE, E ;

ARNASON, BGW ;

NORONHA, A ;

REDER, AT ;

MARTIA, R ;

EBERS, GC ;

RICE, GPA ;

LESAUX, J ;

JOHNSON, KP ;

PANITCH, HS ;

BEVER, CT ;

CONWAY, K ;

WALLENBERG, JC ;

BEDELL, L ;

VANDENNOORT, S ;

WEINSHENKER, B ;

WEISS, W ;

REINGOLD, S ;

PACHNER, A ;

TAYLOR, W .

NEUROLOGY, 1993, 43 (04) :655-661

[3] Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN) [J].

Durelli, L ;

Verdun, E ;

Barbero, P ;

Bergui, M ;

Versino, E ;

Ghezzi, A ;

Montanari, E ;

Zaffaroni, M .

LANCET, 2002, 359 (9316) :1453-1460

[4] Results following development of neutralizing antibodies in PRISMS [J].

Francis, GS ;

Rice, GPA ;

Alsop, JC .

NEUROLOGY, 2005, 65 (01) :48-55

[5] Hepatic reactions during treatment of multiple sclerosis with interferon-β-1a -: Incidence and clinical significance [J].

Francis, GS ;

Grumser, Y ;

Alteri, E ;

Micaleff, A ;

O'Brien, F ;

Alsop, J ;

Moraga, MS ;

Kaplowitz, N .

DRUG SAFETY, 2003, 26 (11) :815-827

[6] The long-term safety and tolerability of high-dose interferon β-1a in relapsing-remitting multiple sclerosis:: 4-year data from the PRISMS study [J].

Gold, R ;

Rieckmann, P ;

Chang, P ;

Abdalla, J .

EUROPEAN JOURNAL OF NEUROLOGY, 2005, 12 (08) :649-656

[7] Intramuscular interferon beta-1 alpha for disease progression in relapsing multiple sclerosis [J].

Jacobs, LD ;

Cookfair, DL ;

Rudick, RA ;

Herndon, RM ;

Richert, JR ;

Salazar, AM ;

Fischer, JS ;

Goodkin, DE ;

Granger, CV ;

Simon, JH ;

Alam, JJ ;

Bartoszak, DM ;

Bourdette, DN ;

Braiman, J ;

Brownscheidle, CM ;

Coats, ME ;

Cohan, SL ;

Dougherty, DS ;

Kinkel, RP ;

Mass, MK ;

Munschauer, FE ;

Priore, RL ;

Pullicino, PM ;

Scherokman, BJ ;

WeinstockGuttman, B ;

Whitman, RH ;

Baird, WC ;

Fillmore, M ;

Bona, LM ;

ColonRuiz, ME ;

Nadine, BS ;

Donovan, A ;

Bennett, S ;

Kieffer, YM ;

Umhauer, MA ;

Miller, CE ;

Kilic, AK ;

Sargent, EL ;

Schachter, M ;

Shucard, DW ;

Weider, V ;

Catalano, BA ;

Cervi, JM ;

Czekay, C ;

Farrell, JL ;

Filippini, JS ;

Matyas, RC ;

Michienzi, KE ;

Ito, M ;

OMalley, JA .

ANNALS OF NEUROLOGY, 1996, 39 (03) :285-294

[8]

Li DKB, 1999, ANN NEUROL, V46, P197, DOI 10.1002/1531-8249(199908)46:2<197::AID-ANA9>3.0.CO

[9]

2-P

[10] Randomized, comparative study of interferon β-1a treatment regimens in MS -: The EVIDENCE trial [J].

Panitch, H ;

Goodin, DS ;

Francis, G ;

Chang, P ;

Coyle, PK ;

O'Connor, P ;

Monaghan, E ;

Li, D ;

Weinshenker, B .

NEUROLOGY, 2002, 59 (10) :1496-1506

← 1 2 →